Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Faculty of Health and Welfare Science, Nayoro City University, Nayoro, Hokkaido 096-8641, Japan.
Molecules. 2020 Jun 2;25(11):2588. doi: 10.3390/molecules25112588.
Most cell-based and animal experiments have shown that green tea catechins (GTC) exhibit various health benefits. In human experimental and epidemiological studies, there are conflicting results, and more precise investigations are required. One of the most effective ways to prove beneficial health effects in humans might be clinical intervention studies. PolyphenonE was developed as a standardized GTC preparation, which was approved by Food and Drug Administration of US in 2006 as a medication to treat genital warts (Veregen or sinecatechins). Positive efficacy of PolyphenonE/sinecatechins/Veregen (PSV) on anogenital warts has been demonstrated in several epidemiological studies and there have been several case reports to show the clinical effectiveness of PSV. In addition, several studies have provided evidence to suggest that PSV is effective in other human papillomavirus (HPV)-related diseases, although some studies failed to show such effects. Since (-)-epigallocatechin gallate (EGCG) is the major component of PSV, the mechanism of the action of PSV might be deduced from that of EGCG. The microarray analysis of the biopsy samples from the patients suggested that apoptosis induction and the downregulation of inflammation are involved in the mechanism of the action of PSV in the clearance of anogenital warts. Cell-based and animal experiments using PSV also demonstrated effects similar to those elicited by EGCG, explaining how PSV works to induce apoptosis and exert anti-inflammatory actions in HPV-related diseases. Future studies would clarify what kinds of diseases respond effectively to PSV, showing health benefits of GTC and EGCG in humans.
大多数基于细胞和动物的实验表明，绿茶儿茶素（GTC）具有多种健康益处。在人类实验和流行病学研究中，结果存在矛盾，需要更精确的调查。证明 GTC 和 EGCG 在人类中具有有益健康作用的最有效方法之一可能是临床干预研究。多酚 E 是一种标准化的 GTC 制剂，于 2006 年被美国食品和药物管理局批准为治疗生殖器疣的药物（Veregen 或 sinecatechins）。多酚 E/鞣花酸/威瑞森（PSV）在几种流行病学研究中已被证明对肛门生殖器疣有效，并且有几个病例报告显示 PSV 的临床疗效。此外，几项研究提供了证据表明 PSV 对其他人类乳头瘤病毒（HPV）相关疾病有效，尽管一些研究未能显示出这种效果。由于（-）-表没食子儿茶素没食子酸酯（EGCG）是 PSV 的主要成分，因此 PSV 的作用机制可以从 EGCG 的作用机制中推断出来。来自患者活检样本的微阵列分析表明，凋亡诱导和炎症下调参与了 PSV 清除肛门生殖器疣的作用机制。使用 PSV 的细胞和动物实验也证明了与 EGCG 相似的效果，解释了 PSV 如何在 HPV 相关疾病中诱导凋亡和发挥抗炎作用。未来的研究将阐明哪些疾病对 PSV 有效，从而在人类中显示 GTC 和 EGCG 的健康益处。
